IN2015DN03969A - - Google Patents
Info
- Publication number
- IN2015DN03969A IN2015DN03969A IN3969DEN2015A IN2015DN03969A IN 2015DN03969 A IN2015DN03969 A IN 2015DN03969A IN 3969DEN2015 A IN3969DEN2015 A IN 3969DEN2015A IN 2015DN03969 A IN2015DN03969 A IN 2015DN03969A
- Authority
- IN
- India
- Prior art keywords
- treatments
- methods
- disorders
- neuropathic
- risk
- Prior art date
Links
- 238000011282 treatment Methods 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 201000011461 pre-eclampsia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1218676.3A GB201218676D0 (en) | 2012-10-17 | 2012-10-17 | Anti-angiogenic treatments |
| GBGB1218758.9A GB201218758D0 (en) | 2012-10-18 | 2012-10-18 | Compounds |
| GB201304694A GB201304694D0 (en) | 2013-03-15 | 2013-03-15 | Compounds |
| PCT/GB2013/052716 WO2014060763A1 (en) | 2012-10-17 | 2013-10-17 | Compounds useful for treating ocular neovasculan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03969A true IN2015DN03969A (enrdf_load_stackoverflow) | 2015-10-02 |
Family
ID=49518992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3969DEN2015 IN2015DN03969A (enrdf_load_stackoverflow) | 2012-10-17 | 2013-10-17 |
Country Status (8)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201406956D0 (en) * | 2014-04-17 | 2014-06-04 | Univ Nottingham | Compounds |
| GB201518365D0 (en) * | 2015-10-16 | 2015-12-02 | Exonate Ltd | Compounds |
| JP6898429B2 (ja) * | 2016-08-24 | 2021-07-07 | ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ，ベイジン | 黄斑変性症を治療するためのエンタカポン関連化合物 |
| WO2019063996A1 (en) * | 2017-09-27 | 2019-04-04 | Exonate Limited | INHIBITORS OF SRPK1 |
| GB202010829D0 (en) * | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
| CN113769073A (zh) * | 2021-10-15 | 2021-12-10 | 杭州鑫伟低碳技术研发有限公司 | 一种利用生物酶治疗眼底出血的方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1052507A (enrdf_load_stackoverflow) | 1963-06-26 | |||
| EP1105120B1 (en) | 1998-08-20 | 2005-03-23 | Agouron Pharmaceuticals, Inc. | NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION |
| FR2840314B1 (fr) | 2002-06-03 | 2004-08-20 | Inst Francais Du Petrole | Methode d'isolation thermique, procede de preparation d'un gel isolant et gel isolant obtenu |
| CA2801848C (en) * | 2003-12-26 | 2015-03-31 | Masatoshi Hagiwara | Methods for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity |
| AU2005245386B2 (en) * | 2004-05-07 | 2008-11-27 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| US7776869B2 (en) * | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| WO2007072041A1 (en) * | 2005-12-23 | 2007-06-28 | Astex Therapeutics Limited | Therapeutic compounds |
| WO2008011077A2 (en) | 2006-07-18 | 2008-01-24 | Thule Sweden Ab | System and method for providing an article organizer to a recreational vehicle |
| AU2007336781C1 (en) * | 2006-12-21 | 2014-10-09 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
| GB0704678D0 (en) * | 2007-03-09 | 2007-04-18 | Univ Bristol | Pro- and anti-angiogenic treatments |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| WO2009020198A1 (ja) * | 2007-08-03 | 2009-02-12 | Kinopharma, Inc. | 抗ｄｎａウイルス作用を有するアニリン誘導体 |
| CN101422603A (zh) | 2007-10-31 | 2009-05-06 | 马万超 | 不溶性生物活性蛋白质作为玻璃体内用药治疗眼科疾病 |
| GB0803912D0 (en) | 2008-02-29 | 2008-05-07 | Univ Bristol | Novel Uses of VEGFxxxb |
| US8765941B2 (en) * | 2008-03-25 | 2014-07-01 | Kino Pharma, Inc. | Aniline derivative having anti-RNA viral activity |
| JP2012509306A (ja) | 2008-11-22 | 2012-04-19 | ザ ユニバーシティ オブ ブリストル | ＶＥＧＦｘｘｘｂの新規な使用 |
| WO2011036429A1 (en) | 2009-09-25 | 2011-03-31 | The University Of Bristol | Detection of risk of pre-eclampsia |
| US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
| GB201009173D0 (en) | 2010-05-28 | 2010-07-14 | Univ Bristol | Treatment of pain |
| EP2632462A1 (en) * | 2010-10-29 | 2013-09-04 | Merck Sharp & Dohme Corp. | Novel heteroaryl-carboxamide derivatives as pdk1 inhibitors |
| GB201406956D0 (en) * | 2014-04-17 | 2014-06-04 | Univ Nottingham | Compounds |
-
2013
- 2013-10-17 IN IN3969DEN2015 patent/IN2015DN03969A/en unknown
- 2013-10-17 EP EP13786300.7A patent/EP2908811B1/en active Active
- 2013-10-17 US US14/436,727 patent/US10301264B2/en active Active
- 2013-10-17 JP JP2015537351A patent/JP2016504270A/ja active Pending
- 2013-10-17 ES ES13786300T patent/ES2858511T3/es active Active
- 2013-10-17 WO PCT/GB2013/052716 patent/WO2014060763A1/en not_active Ceased
- 2013-10-17 CN CN201380065738.XA patent/CN104869990B/zh active Active
- 2013-10-17 AU AU2013333657A patent/AU2013333657B2/en active Active
-
2018
- 2018-08-10 JP JP2018151511A patent/JP6738512B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014060763A1 (en) | 2014-04-24 |
| JP2018203748A (ja) | 2018-12-27 |
| EP2908811B1 (en) | 2020-12-09 |
| ES2858511T3 (es) | 2021-09-30 |
| AU2013333657B2 (en) | 2018-04-26 |
| CN104869990A (zh) | 2015-08-26 |
| JP2016504270A (ja) | 2016-02-12 |
| JP6738512B2 (ja) | 2020-08-12 |
| AU2013333657A1 (en) | 2015-05-28 |
| EP2908811A1 (en) | 2015-08-26 |
| US10301264B2 (en) | 2019-05-28 |
| US20150274668A1 (en) | 2015-10-01 |
| CN104869990B (zh) | 2022-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3297644A4 (en) | Methods for treating autism spectrum disorder and associated symptoms | |
| EP2991670B8 (en) | Sobetirome in the treatment of myelination diseases | |
| MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
| EP2756740A4 (en) | COLD PLASMA PROCESSING DEVICES AND ASSOCIATED METHODS | |
| IL225239A0 (en) | Compounds for the treatment of acne and related diseases | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| WO2014138429A3 (en) | Peptidomimetic macrocycles and use thereof in regulating hif1alpha | |
| HK1206393A1 (en) | Compositions and methods for diagnosis and treatment of pervasive developmental disorder | |
| EP2830654B8 (en) | Methods and compositions for treating inflammation | |
| EP3068492A4 (en) | Neurodegenerative disorders and methods of treatment and diagnosis thereof | |
| MX365403B (es) | Peptidos y metodos para usarlos. | |
| EP3008167A4 (en) | Compositions and methods for treating metabolic disorders | |
| EP3041577A4 (en) | Treatment and prevention of autism and autism spectrum disorders | |
| ZA201300954B (en) | Methods for treating and/or reversing neurodegenerative deseases and/or disorders | |
| IN2015DN03969A (enrdf_load_stackoverflow) | ||
| EP2986308A4 (en) | Angiotensin ii alone or in combination for the treatment of hypotension | |
| LT2854910T (lt) | Ceramido lygiai infekcijos gydymo ir prevencijos metu | |
| EP2825194A4 (en) | USE OF ANTITHROMBINE IN THE TREATMENT OF PRE-ECLAMPSIA | |
| IL233141A0 (en) | Combined treatment of hearing and balance disorders | |
| EP3099638A4 (en) | Wastewater treatment process and system | |
| PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
| EP3060566A4 (en) | Compounds for use in prevention and treatment of neurodegenerative diseases and pain | |
| NZ711523A (en) | Use of sedoheptulose for prevention or treatment of inflammation | |
| PL3040329T3 (pl) | Związek aromatyczny i jego zastosowanie w leczeniu chorób związanych z metabolizmem kości | |
| EP2994147A4 (en) | Compositions and methods for the treatment of tinnitus |